Status:
COMPLETED
Long-Term Supervised Treatment Interruption in HIV-Infected Patients
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is aimed at studying the safety of long term supervised treatment interruption in HIV infected patients with CD4 over 350/mm3 and plasma HIV RNA under 50 000/mL. Another aim of this study i...
Detailed Description
The limitations of the drugs used against HIV include their toxicity, their tolerability, their propensity to induce resistance when not taken with absolute regularity and their cost. Treatment interr...
Eligibility Criteria
Inclusion
- Males and non pregnant females
- 18 years of age and older
- Who have confirmed laboratory diagnosis of HIV infection
- Started on first line antiretroviral treatment with CD4 over 350/mm3 and plasma HIV RNA below 50 000/mL
- Ongoing Antiretroviral therapy at inclusion with CD4 over 450/mm3 and plasma HIV RNA below 5000/mL
Exclusion
- HBV-HIV co-infection receiving lamivudine therapy
- Ongoing immunotherapy including IL2, interferon or HIV specific vaccine
- Pregnancy or project of pregnancy
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00118677
Start Date
February 1 2003
End Date
May 1 2007
Last Update
August 30 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'immunologie Clinique, Höpital Européen Georges Pompidou
Paris, France, 75015